Entera Bio raises oversubscribed $275M private placement led by BVF Partners
What's the deal? Entera Bio has priced an oversubscribed $275 million private placement, led by existing investor BVF PartnersDealroom has a profile for this one. Try Dealroom → L.P. The Israel-based company announced the pricing on July 27, 2026.
Why now? The round was oversubscribed, signalling investor demand outstripped the offering. BVF Partners, an existing backer, led the raise.
The signal: At $275 million, the deal ranks in the 96th percentile of private placement rounds in Israel's health sector over the trailing 48 months, based on a sample of 456 rounds — a standout figure that reflects continued appetite for late-stage biotech financing.
Read more: aktiencheck.de
Image credit: Entera Bio
